WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006082089) ORAL DOSAGE FORM COMPRISING ROSIGLITAZONE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/082089    International Application No.:    PCT/EP2006/000999
Publication Date: 10.08.2006 International Filing Date: 03.02.2006
IPC:
A61K 31/427 (2006.01), A61K 9/16 (2006.01), A61K 9/48 (2006.01), A61P 3/10 (2006.01)
Applicants: SB PHARMCO PUERTO RICO INC. [US/US]; The Prentice Hall Corp. System, c/o FGR Corporate Services, Inc., BBV Tower, 8th Floor, 254 Munoz Rivera Avenue, San Juan, Puerto Rico 00918 (US) (For All Designated States Except US).
RE, Vincenzo [GB/GB]; (GB) (For US Only)
Inventors: RE, Vincenzo; (GB)
Agent: THORNLEY, Rachel, Mary; GlaxoSmithKline, Corporate Intellectual Property (cn925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB)
Priority Data:
0502479.9 07.02.2005 GB
Title (EN) ORAL DOSAGE FORM COMPRISING ROSIGLITAZONE
(FR) FORME POSOLOGIQUE ORALE CONTENANT DE LA ROSIGLITAZONE
Abstract: front page image
(EN)An oral dosage form comprising pellets of a first composition and pellets of a second composition, each composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release drug at differing release rates on administration, preferably such that the rate of release of the drug from the dosage form is substantially independent of pH; a process for preparing such a dosage form and the use of such a dosage form in medicine.
(FR)L'invention concerne une forme posologique orale comprenant des granules d'une première composition et des granules d'une seconde composition, chaque composition contenant une 5-[4-[2-(N-méthyl-N-(2 pyridyl)amino)éthoxy]benzyl]thiazolidine-2,4-dione ou un sel ou solvate pharmaceutiquement acceptable de cette dernière et un vecteur pharmaceutiquement acceptable pour ledit composé, les première et seconde compositions étant conçues pour libérer le médicament à différentes vitesses de libération lors de l'administration, de préférence de sorte que la vitesse de libération du médicament de la forme posologique est sensiblement indépendante du pH. Cette invention concerne également un procédé de préparation d'une forme posologique de ce type et l'utilisation de cette forme posologique en médecine.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)